Variations of High Sensitivity Troponin T in Neonates
Launched by HÔPITAL NOVO · Aug 25, 2016
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
* Approximately 400 subjects will be recruited over a planned recruitment period of 2 months. During labour, or pre natal hospitalization, information about the study will be given to every mothers by the midwife or the pediatrician. Absence of opposition will be notified in the medical file.
* At birth, every child born alive is possibly eligible for this study, if he doesn't meet the exclusion criteria.
* After clamping the umbilical cord, the midwife realizes the systematic sample for assessment of pH and lactate. If the mother did not object to the study, the midwife will use 200µl of t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Every newborn, born alive in René Dubos maternity, without regarding the way of birth.
- • Absence of malformative syndromes or genetic abnormalities in prenatal echographies
- • Absence of parental opposition
- Exclusion Criteria:
- • Multiple pregnancies
- • Post natal discovery of malformative syndromes or genetic abnormality. All congenital heart diseases will be excluded.
- • Parental opposition at any time of the study
About Hôpital Novo
Hôpital Novo is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a strong emphasis on collaboration and ethical practices, Hôpital Novo partners with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. Their commitment to patient safety, data integrity, and regulatory compliance ensures that all research initiatives are conducted to the highest standards, ultimately contributing to the development of new treatments and therapies that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pontoise, Val D'oise, France
Patients applied
Trial Officials
BORRHOMEE Suzanne, PH
Principal Investigator
suzanne.borrhomee@gmail.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials